ID   KE-39
AC   CVCL_3385
SY   KE39
DR   CLO; CLO_0050802
DR   ArrayExpress; E-MTAB-2770
DR   BioSample; SAMN03470990
DR   BioSample; SAMN03472139
DR   BioSample; SAMN10987859
DR   cancercelllines; CVCL_3385
DR   Cell_Model_Passport; SIDM01582
DR   Cosmic; 1187280
DR   DepMap; ACH-000507
DR   GEO; GSM887204
DR   GEO; GSM888277
DR   IARC_TP53; 28288
DR   LiGeA; CCLE_164
DR   PharmacoDB; KE39_741_2019
DR   Progenetix; CVCL_3385
DR   RCB; RCB1434
DR   Wikidata; Q54899716
RX   PubMed=7599112;
RX   PubMed=22460905;
RX   PubMed=24587255;
RX   PubMed=24807215;
RX   PubMed=25877200;
RX   PubMed=30894373;
RX   PubMed=31068700;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Population: Japanese.
CC   Doubling time: ~38.4 hours (PubMed=7599112).
CC   Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Asp32Asn (c.94G>A); ClinVar=VCV000376228; Zygosity=Heterozygous (DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val272Leu (c.814G>T); ClinVar=VCV000012358; Zygosity=Homozygous (DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=1.5%; Native American=0%; East Asian, North=89.52%; East Asian, South=4.53%; South Asian=0%; European, North=0%; European, South=4.45% (PubMed=30894373).
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000027.
ST   Source(s): PubMed=25877200; RCB
ST   Amelogenin: X
ST   CSF1PO: 13
ST   D13S317: 8,10
ST   D16S539: 11
ST   D18S51: 14,15
ST   D19S433: 14.2,16.2
ST   D21S11: 30
ST   D2S1338: 22
ST   D3S1358: 17
ST   D5S818: 10
ST   D7S820: 11
ST   D8S1179: 11,16
ST   FGA: 22,23
ST   Penta D: 11
ST   Penta E: 18,23
ST   TH01: 7 (PubMed=25877200)
ST   TH01: 7,9.3 (RCB)
ST   TPOX: 9,11
ST   vWA: 14
DI   NCIt; C4004; Gastric adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   77Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 22
//
RX   PubMed=7599112;
RA   Uesugi H., Yamashita K., Atari E., Shinoda H., Nishiyama T.,
RA   Okayasu I., Yasuda S.;
RT   "Establishment and characterization of strain KE-39 derived from human
RT   gastric cancer.";
RL   Hum. Cell 7:227-232(1994).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=24587255; DOI=10.1371/journal.pone.0090155;
RA   Endo F., Nishizuka S.S., Kume K., Ishida K., Katagiri H., Ishida K.,
RA   Sato K., Iwaya T., Koeda K., Wakabayashi G.;
RT   "A compensatory role of NF-kappaB to p53 in response to 5-FU-based
RT   chemotherapy for gastric cancer cell lines.";
RL   PLoS ONE 9:E90155-E90155(2014).
//
RX   PubMed=24807215; DOI=10.1038/ncomms4830;
RA   Liu J.-F., McCleland M.L., Stawiski E.W., Gnad F., Mayba O., Haverty P.M.,
RA   Durinck S., Chen Y.-J., Klijn C., Jhunjhunwala S., Lawrence M.,
RA   Liu H.-B., Wan Y.-N., Chopra V.S., Yaylaoglu M.B., Yuan W.-L., Ha C.,
RA   Gilbert H.N., Reeder J., Pau G., Stinson J., Stern H.M., Manning G.,
RA   Wu T.D., Neve R.M., de Sauvage F.J., Modrusan Z., Seshagiri S.,
RA   Firestein R., Zhang Z.-M.;
RT   "Integrated exome and transcriptome sequencing reveals ZAK isoform
RT   usage in gastric cancer.";
RL   Nat. Commun. 5:3830.1-3830.8(2014).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//